Lilly's Next-Gen Drug Tops Zepbound on Weight Loss in Late-Stage Osteoarthritis Trial
Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis. In the trial, participants taking retatrutide 12 mg achieved an average weight loss of 28.7% from baseline at 68 weeks, and experienced a reduction in osteoarthritis pain by up to 4.5 points on the WOMAC pain score. Improvements in physical function were also observed, with more than one in eight patients becoming free from knee pain by the end of the trial. Discontinuation rates due to adverse events were higher in the retatrutide groups compared to placebo. Detailed results from TRIUMPH-4 will be presented at a future medical meeting and published in a peer-reviewed journal. Additional Phase 3 trials in the TRIUMPH program are ongoing, with results expected in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet